Related Experiment Videos
Amyloidosis in continuous ambulatory peritoneal dialysis
M Beaman1, A P Boon, J Michael
1Department of Nephrology, Queen Elizabeth Hospital, Edgbaston, Birmingham, UK.
Postgraduate Medical Journal
|August 1, 1987
Abstract:
We report a 53 year old man with chronic renal failure on continuous ambulatory peritoneal dialysis. Following eight episodes of severe peritonitis over a 2 year period, he died and was found to have widespread AA amyloid at post-mortem.
Insights
A patient with chronic renal failure undergoing peritoneal dialysis developed severe peritonitis multiple times. Post-mortem examination revealed widespread AA amyloidosis, highlighting a potential complication of long-term dialysis.
Area of Science:
- Nephrology
- Pathology
- Internal Medicine
Background:
- Chronic renal failure necessitates renal replacement therapy, such as peritoneal dialysis.
- Peritoneal dialysis is a common treatment for end-stage renal disease.
- Recurrent peritonitis is a known complication of peritoneal dialysis.
Observation:
- A 53-year-old male patient with chronic renal failure was on continuous ambulatory peritoneal dialysis.
- The patient experienced eight episodes of severe peritonitis over a two-year period.
- The patient ultimately died due to complications related to his condition.
Findings:
- Post-mortem examination revealed widespread deposition of AA amyloid.
- AA amyloidosis is a form of secondary amyloidosis associated with chronic inflammation.
- The findings suggest a link between recurrent peritonitis and the development of AA amyloidosis in this patient.
Implications:
- This case highlights the potential for severe AA amyloidosis to develop in patients with chronic renal failure undergoing peritoneal dialysis, particularly with recurrent peritonitis.
- Further research may be warranted to investigate the mechanisms linking peritoneal dialysis-associated inflammation and amyloidosis.
- Clinical vigilance for AA amyloidosis in dialysis patients with refractory peritonitis is suggested.